Grifols (GRFS) Assets Average (2011 - 2025)
Grifols (GRFS) reported Assets Average of $22.9 billion for Q4 2025, up 0.79% on a YoY basis from $22.7 billion in Q4 2024, and up 0.79% quarter-over-quarter from $22.7 billion in Q4 2024.
Grifols (GRFS) Assets Average (2011 - 2025) Analysis & Trends
Grifols has reported Assets Average for 15 years, with the latest figure at $22.9 billion in Q4 2025.
- For the quarter ending Q4 2025, Assets Average rose 0.79% year-over-year to $22.9 billion; the trailing twelve-month figure through Dec 2025 stood at $22.9 billion (up 0.79% YoY), and the FY2025 full-year result was $11.5 billion, up 9184.56% from the prior year.
- Assets Average for Q4 2025 stood at $22.9 billion, up from $22.7 billion in the prior quarter.
- The five-year high for Assets Average was $22.9 billion in Q4 2025, with the low at $20.1 billion in Q4 2021.
- Historically, Assets Average has averaged $21.9 billion across 5 years, with a median of $22.1 billion in 2023.
- Annual changes were most pronounced in 2021 — Assets Average grew 10.21% — and 2025, when it increased 0.79%.
- Grifols' Assets Average stood at $20.1 billion in 2021, then climbed by 8.57% to $21.8 billion in 2022, then climbed by 1.34% to $22.1 billion in 2023, then advanced by 2.74% to $22.7 billion in 2024, then rose by 0.79% to $22.9 billion in 2025.
- The last three Assets Average figures came in at $22.9 billion (Q4 2025), $22.7 billion (Q4 2024), and $22.1 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 83.03 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 114.53 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 200.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 135.21 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 88.26 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | 22.91 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.91 Bn |
| Dec 31, 2024 | 22.73 Bn |
| Dec 31, 2023 | 22.12 Bn |
| Dec 31, 2022 | 21.83 Bn |
| Dec 31, 2021 | 20.11 Bn |
| Dec 31, 2020 | 18.24 Bn |
| Sep 30, 2020 | 17.91 Bn |
| Mar 31, 2020 | 17.38 Bn |
| Dec 31, 2019 | 16.41 Bn |
| Sep 30, 2019 | 15.42 Bn |
| Mar 31, 2019 | 14.73 Bn |
| Dec 31, 2018 | 13.97 Bn |
| Sep 30, 2018 | 13.67 Bn |
| Jun 30, 2018 | 15.05 Bn |
| Mar 31, 2018 | 14.65 Bn |
| Dec 31, 2017 | 12.54 Bn |
| Dec 31, 2016 | 10.81 Bn |
| Sep 30, 2016 | 10.73 Bn |
| Jun 30, 2016 | 10.48 Bn |
| Mar 31, 2016 | 10.36 Bn |